The GMR Clinical Trials Unit will soon be recruiting for the following lung clinical trial:
PROTOCOL: 20200041 (PI: Dr kenneth o’byrne) – now recruiting
Protocol Title: A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
Lay Title: Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First-Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLphi-305).
Click here for more information
Protocol: ca224-1093 (PI: Dr kenneth o’byrne)
Protocol Title: A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression of 1% to 49%.
Lay Title: A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49%.
Click here for more information
PROTOCOL: IM043-004 (PART 2) (PI: DR KENNETH O’BYRNE)
Protocol Title: A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
Lay Title: A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
Click here for more information